Expert Panel Discussion: Complicated Treatment Decisions in NSCLC
PROGRAM DESCRIPTION Each year, it has become more complicated to factor in new data to optimize therapeutic management for patients with lung cancer. However, it continues to become more interesting ...
PROGRAM DESCRIPTION
Each year, it has become more complicated to factor in new data to optimize therapeutic management for patients with lung cancer. However, it continues to become more interesting as we optimize therapy for individual patients, with the goal of maximizing benefit and minimizing toxicity. Consequently, oncologists must work closely with pathologists to ensure appropriate testing has been done prior to initiating therapy. We have gathered a panel of experts to discuss some of the more complicated treatment decisions in representative lung cancer clinical scenarios, highlighting both the agreement and differences in treatment decisions between the panel members.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant will be better able to:Assess the most current safety and efficacy data and guideline recommendations associated with evidence-based targeted therapiesSelect the most appropriate patients for anti-VEGF therapy based on individualized characteristics, comorbidities, risk factors, and current clinical evidenceIdentify the role of novel immunotherapies in the use of individualized targeted therapies for advanced NSCLCIncorporate updated genomic testing guidelines and streamlined algorithms for evidence-based targeted treatments of NSCLC patients
Read more about this
Write the first review
Join now
to leave a review or read peer reviews!
Resource tags
Show all tags